Corvus Pharmaceuticals Inc (NASDAQ:CRVS) Expected to Announce Earnings of -$0.33 Per Share

Wall Street brokerages predict that Corvus Pharmaceuticals Inc (NASDAQ:CRVS) will post earnings per share (EPS) of ($0.33) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Corvus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.29). Corvus Pharmaceuticals reported earnings per share of ($0.36) in the same quarter last year, which suggests a positive year over year growth rate of 8.3%. The company is expected to issue its next quarterly earnings results on Thursday, March 5th.

On average, analysts expect that Corvus Pharmaceuticals will report full year earnings of ($1.53) per share for the current year, with EPS estimates ranging from ($1.60) to ($1.47). For the next financial year, analysts anticipate that the firm will post earnings of ($1.27) per share, with EPS estimates ranging from ($1.39) to ($1.06). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Corvus Pharmaceuticals.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.05.

CRVS has been the subject of several recent research reports. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a research report on Friday, November 1st. Mizuho restated a “buy” rating and issued a $7.00 price objective on shares of Corvus Pharmaceuticals in a research report on Tuesday, October 29th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $6.94.

Shares of CRVS stock opened at $3.45 on Wednesday. The stock has a 50 day moving average of $3.25 and a 200 day moving average of $3.93. The company has a current ratio of 9.23, a quick ratio of 9.23 and a debt-to-equity ratio of 0.03. Corvus Pharmaceuticals has a twelve month low of $2.53 and a twelve month high of $8.10.

Institutional investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $50,000. Paloma Partners Management Co purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $149,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $223,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Corvus Pharmaceuticals by 9.1% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 64,325 shares of the company’s stock valued at $241,000 after buying an additional 5,374 shares in the last quarter. Finally, Fosun International Ltd increased its position in shares of Corvus Pharmaceuticals by 7.7% in the second quarter. Fosun International Ltd now owns 184,116 shares of the company’s stock valued at $624,000 after buying an additional 13,142 shares in the last quarter. Institutional investors and hedge funds own 82.83% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Featured Article: Stocks Increasing Dividends

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.